232 related articles for article (PubMed ID: 30686641)
21. Sacubitril/valsartan improves both functional and echocardiographic parameters in patients with chronic heart failure with reduced ejection fraction.
Cosentino ER; Degli Esposti D; Miceli R; Bentivenga C; Landolfo M; Fg Cicero A; Berardi E; Spinardi L; Magri G; Dugato V; Borghi C
Curr Med Res Opin; 2019 Mar; 35(sup1):9-12. PubMed ID: 30864900
[TBL] [Abstract][Full Text] [Related]
22. Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction.
Martens P; Nuyens D; Rivero-Ayerza M; Van Herendael H; Vercammen J; Ceyssens W; Luwel E; Dupont M; Mullens W
Clin Res Cardiol; 2019 Oct; 108(10):1074-1082. PubMed ID: 30788621
[TBL] [Abstract][Full Text] [Related]
23. Effects of sacubitril/valsartan on B-type natriuretic peptide circulating levels and loop diuretic dose in a case series of stabilized heart failure patients with left ventricular ejection fraction ≤35.
Pugliese NR; Fabiani I; Zywicki V; Mazzola M; D'Agostino A; Galeotti GG; Dini FL
Curr Med Res Opin; 2019 May; 35(sup3):13-18. PubMed ID: 30895809
[TBL] [Abstract][Full Text] [Related]
24. [Sacubitril / Valsartan in patients with diabetes and heart failure].
Brandenburg VM; Rocca HB; Marx N
Dtsch Med Wochenschr; 2016 Oct; 141(22):1647-1649. PubMed ID: 27824422
[TBL] [Abstract][Full Text] [Related]
25. Sacubitril/Valsartan in Real-Life Practice: Experience in Patients with Advanced Heart Failure and Systematic Review.
Moliner-Abós C; Rivas-Lasarte M; Pamies Besora J; Fluvià-Brugues P; Solé-González E; Mirabet S; López López L; Brossa V; Pirla MJ; Mesado N; Álvarez-García J; Roig E
Cardiovasc Drugs Ther; 2019 Jun; 33(3):307-314. PubMed ID: 30820802
[TBL] [Abstract][Full Text] [Related]
26. Sacubitril/valsartan in the treatment of systemic right ventricular failure.
Zandstra TE; Nederend M; Jongbloed MRM; Kiès P; Vliegen HW; Bouma BJ; Tops LF; Schalij MJ; Egorova AD
Heart; 2021 Nov; 107(21):1725-1730. PubMed ID: 33452121
[TBL] [Abstract][Full Text] [Related]
27. Titration and Tolerability of Sacubitril/Valsartan for Patients With Heart Failure in Clinical Practice.
Du AX; Westerhout CM; McAlister FA; Shanks M; Oudit GY; Paterson DI; Hanninen M; Thomas J; Ezekowitz JA
J Cardiovasc Pharmacol; 2019 Mar; 73(3):149-154. PubMed ID: 30540684
[TBL] [Abstract][Full Text] [Related]
28. Effect of sacubitril/valsartan on cardiac filling pressures in patients with left ventricular systolic dysfunction.
Khan Z; Gholkar G; Tolia S; Kado H; Zughaib M
Int J Cardiol; 2018 Nov; 271():169-173. PubMed ID: 30093137
[TBL] [Abstract][Full Text] [Related]
29. Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation.
Kang DH; Park SJ; Shin SH; Hong GR; Lee S; Kim MS; Yun SC; Song JM; Park SW; Kim JJ
Circulation; 2019 Mar; 139(11):1354-1365. PubMed ID: 30586756
[TBL] [Abstract][Full Text] [Related]
30. Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial.
Chandra A; Lewis EF; Claggett BL; Desai AS; Packer M; Zile MR; Swedberg K; Rouleau JL; Shi VC; Lefkowitz MP; Katova T; McMurray JJV; Solomon SD
JAMA Cardiol; 2018 Jun; 3(6):498-505. PubMed ID: 29617523
[TBL] [Abstract][Full Text] [Related]
31. Impact of sacubitril-valsartan combination in patients with chronic heart failure and sleep apnoea syndrome: the ENTRESTO-SAS study design.
Jaffuel D; Molinari N; Berdague P; Pathak A; Galinier M; Dupuis M; Ricci JE; Mallet JP; Bourdin A; Roubille F
ESC Heart Fail; 2018 Jun; 5(3):222-230. PubMed ID: 29469206
[TBL] [Abstract][Full Text] [Related]
32. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
Hubers SA; Brown NJ
Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
[TBL] [Abstract][Full Text] [Related]
33. Real-world treatment switching to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A cohort study.
Ganesananthan S; Shah N; Shah P; Elsayed H; Phillips J; Parkes A; Morgan A; Yousef Z
Open Heart; 2020 Oct; 7(2):. PubMed ID: 33020255
[TBL] [Abstract][Full Text] [Related]
34. Cost-Effectiveness of Switching Patients With Heart Failure and Reduced Ejection Fraction to Sacubitril/Valsartan: The Australian Perspective.
Chin KL; Zomer E; Wang BH; Liew D
Heart Lung Circ; 2020 Sep; 29(9):1310-1317. PubMed ID: 32303468
[TBL] [Abstract][Full Text] [Related]
35. What proportion of patients with chronic heart failure are eligible for sacubitril-valsartan?
Pellicori P; Urbinati A; Shah P; MacNamara A; Kazmi S; Dierckx R; Zhang J; Cleland JGF; Clark AL
Eur J Heart Fail; 2017 Jun; 19(6):768-778. PubMed ID: 28244205
[TBL] [Abstract][Full Text] [Related]
36. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial.
Desai AS; Vardeny O; Claggett B; McMurray JJ; Packer M; Swedberg K; Rouleau JL; Zile MR; Lefkowitz M; Shi V; Solomon SD
JAMA Cardiol; 2017 Jan; 2(1):79-85. PubMed ID: 27842179
[TBL] [Abstract][Full Text] [Related]
37. Rationale and methods of the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF).
Januzzi JL; Butler J; Fombu E; Maisel A; McCague K; Piña IL; Prescott MF; Riebman JB; Solomon S
Am Heart J; 2018 May; 199():130-136. PubMed ID: 29754651
[TBL] [Abstract][Full Text] [Related]
38. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study.
Wachter R; Senni M; Belohlavek J; Straburzynska-Migaj E; Witte KK; Kobalava Z; Fonseca C; Goncalvesova E; Cavusoglu Y; Fernandez A; Chaaban S; Bøhmer E; Pouleur AC; Mueller C; Tribouilloy C; Lonn E; A L Buraiki J; Gniot J; Mozheiko M; Lelonek M; Noè A; Schwende H; Bao W; Butylin D; Pascual-Figal D;
Eur J Heart Fail; 2019 Aug; 21(8):998-1007. PubMed ID: 31134724
[TBL] [Abstract][Full Text] [Related]
39. Sacubitril and valsartan fixed combination to reduce heart failure events in post-acute myocardial infarction patients.
Zaid Iskandar M; Lang CC
Drugs Today (Barc); 2017 Oct; 53(10):545-551. PubMed ID: 29286056
[TBL] [Abstract][Full Text] [Related]
40. Impact of sacubitril/valsartan on heart failure admissions: insights from real-world patient prescriptions.
Martens P; Lambeets S; Lau CW; Dupont M; Mullens W
Acta Cardiol; 2019 Apr; 74(2):115-122. PubMed ID: 29909743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
